NDAINJECTIONINJECTABLEPriority Review
Approved
Feb 1999
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Mechanism of Action
Alkylating Activity
Pharmacologic Class:
Alkylating Drug
Indications (1)
Clinical Trials (5)
Busulfan, Melphalan, Escalating Carfilzomib Conditioning Auto Stem Cell Transplantation for Multiple Myeloma (MM)
Started May 2019
36 enrolled
Multiple Myeloma
Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype
Started Jun 2016
8 enrolled
Lymphoma
Busulfan & Melphalan Conditioning for Autologous Stem Cell Transplant (ASCT) and Lenalidomide Maintenance
Started Oct 2013
78 enrolled
Multiple Myeloma
Bortezomib (Velcade®), Lenalidomide (Revlimid®) and IV Busulfan (Busilvex®) in Patients Under 65 Years Old
Started Sep 2013
460 enrolled
Multiple Myeloma
Busulfan and Melphalan Conditioning in Multiple Myeloma
Started Jan 2013
105 enrolled
Multiple Myeloma